A question for the scientists here: What's your take on Thorpe's assertion that chimeric Bavi is as good as human anti-PS antibody? He must be talking about current short-term dosing regimens and not chronic administration. Also, surprised by his answer to whether Bavi works better in less severely ill patients: "They'are all pretty sick" is not much of an answer, even though true. That information is pretty important.Intriguing that Bavi helps body defences develop immunity to a cancer cell line; that Bavi seems to work well with almost all anti-cancer agents; that it is probably active against non-solid cancers, such as leukemias and lymphomas; and that after it induces tumor vascular collapse Bavi turns on the actual tumor cells. Things are really going to get interesting when we can use Bavi in treating smaller tumors rather than end-stage disease.
News 
Market Data 
Discover 
AI
